CasNo.265121-04-8,Fosaprepitant Dimeglumine,(265121-04-8) Suppliers

1 Kilogram	Negotiable

Min.Order :1 Kilogram
Purity: 99%
Payment Terms : L/C,D/A,D/P,T/T,Other

Keywords

Fosaprepitant Dimeglumine 265121-04-8 2C7H17NO5*C23H22F7N4O6P

Quick Details

Appearance:White to Off-white powder
Application:Antiemesis
PackAge:bag/bottle/drum(as per customer requirement)
ProductionCapacity:||
Storage:In cool ,dry place
Transportation:Air/Sea/Courier

Superiority:

GMP DMF are available

Tianrui Biopharm is aiming to achieve integration and scale in R&D, production, and sales, committed to becoming a world-class service provider of high value-added API in biopharmaceuticals.
1.We have the best quality and competitive prices.
2.Ensure long-term supply;
3.Fast delivery;
4.Good payment term;
5.Have export experience in many countries.

Details:

Yichang Humanwell Pharmaceutical Co., LTD., established in August 2001, is a leading enterprise in China‘s narcotic drug industry. It located in No.19, Dalian Road, Development district, Yichang, Hubei, China. The listed companies Humanwell Healthcare and China National Pharmaceutical Group Co., Ltd. (Sinopharm) are the first and second largest shareholders of the company. Yichang Humanwell Pharmaceutical Co., Ltd currently has 6 sites. It employs 7000＋ people (including more than 1200 R&D technicians)

Yichang Tianrui Biopharm CO., LTD (Tianrui Biopharm), a wholly-owned subsidiary of Yichang Humanwell Pharmaceutical CO., LTD, was established on November 15, 2022, located in Baiyang Bio- industrial Park of Yichang Hi-tech Development Zone in Hubei Province. We mainly engage in the comprehensive services of research and development, production, and sales of high value-added APIs (including intermediates). With a total investment of about 277 million USD, covering an area of 220,000 square meters, our plant is designed with 13 GMP workshops and constructed in three phases. Currently, phases one and two have been completed, with an investment of about 112 million USD, including 2 GMP commercialized workshops and 9 production lines. We undertake API CMO/CDMO business, with a research and development center built according to the highest domestic standards in China. We are aiming to achieve integration and scale in R&D, production, and sales, committed to becoming a world-class service provider of high value-added API in biopharmaceuticals.